VIENNA, Va., April 26 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(AMEX: CVM) announces the issuance of a U.S. patent for a new platform
technology. This technology can be used for the treatment of a number of
major diseases including autoimmune disease, asthma, allergy and transplant
rejection. This patent, U.S. Patent 7,199,216, is titled "Peptide
constructs for treating autoimmune and related diseases."
This breakthrough T-cell modulation platform technology is called
"AdapT," which stands for "Antigen Directed Apoptosis". AdapT technology
uses proprietary two-peptide molecular constructs to selectively cause the
death of only those immune T-cells that are involved in autoimmune disease,
asthma, allergy, and transplant rejection, by having these disease causing
T-cells undergo apoptosis (programmed cell death) and anergy (a state of
immune unresponsiveness).
It has been well established in the scientific literature that at least
two signals are required for T-cell activation and that, if only one signal
is supplied to T-cells without the ability of the same T-cells to receive a
second activation signal, these T-cells undergo "programmed cell death."
The AdapT molecular constructs capitalize on this well known principle and
"work" by engaging the antigen-specific T-cell receptor with one of its
peptides and, at the same time, block and inhibit the second signal needed
for the full activation of these disease causing T-cells. This single
engagement (T-cell receptor occupation), in the absence of the required
"second signal" for T- cell activation, causes these antigen-specific
disease causing T-cells to self-destruct and die, thereby leading to the
treatment and prevention of these debilitating diseases.
The advantage of the AdapT technology derives from its ability to
selectively remove the disease causing T-cell clones from the host (humans
and animals) following the administration of the AdapT construct(s).
Current treatments of these diseases generally utilize non-specific
immunosuppressants, immunomodulatory compounds or cytokines. The use of an
antigen-specific technology to regulate the immune response and the T-cells
causing disease has a distinct advantage over the use of non-specific
immunosuppressants because the AdapT technology should limit or even
eliminate the unwanted side effects of the currently available
immunosuppressant drugs.
Dr. Eyal Talor, Senior Vice President of Research and Manufacturing at
CEL-SCI and the inventor of this technology said, "The AdapT technology
provides for a way to target only those T-cells that cause disease. This
new approach should give us the ability to markedly decrease or completely
retard the disease process, and at the same time avoid the negative effects
on the healthy part of the immune system - thus, treating the disease and
at the same time keeping the rest of the immune response intact."
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland. The Company has received the go-ahead
from the U.S. FDA and the Canadian Regulators to conduct a Phase III
clinical trial in advanced primary head and neck cancer patients with its
lead product Multikine(R). CEL-SCI's other products, which are currently in
pre-clinical stage and have been funded with U.S. government support, have
shown protection against a number of diseases in animal tests and are
currently being tested against diseases associated with bio-defense and
avian flu.
When used in this report, the words "intends," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Such statements are subject to risks
and uncertainties, which could cause actual results to differ materially
from those projected. Factors that could cause or contribute to such
differences include, an inability to duplicate the clinical results
demonstrated in clinical studies, timely development of any potential
products that can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the Company's
potential products, inability to raise the necessary capital, inability to
get American Stock exchange approval for any transaction and the risk
factors set forth from time to time in CEL-SCI Corporation's SEC filings,
including but not limited to its report on Form 10- K for the year ended
September 30, 2006. The Company undertakes no obligation to publicly
release the result of any revision to these forward-looking statements,
which may be made to reflect the events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
